CDx

The U.S. FDA provides specific guidance for CDx labeling. The labeling is often reviewed in parallel with the therapeutic product and must be consistent with the drug’s approved label (Section 14: Clinical Studies).

FDA expects the following in PMA submissions:

• Exact therapeutic indication: “for selection of patients with [mutation X] for treatment with [drug name]”
• Analytical performance summary: LOD, LOQ, precision (e.g., CV% ≤ 15%)
• Clinical validation summary: Sensitivity, specificity, PPA/NPA with 95% CI
• Human readability: Labeling should be understandable by lab personnel

Access FDA’s template via FDA Labeling Guidance for IVDs.

IVDR Requirements: EMA and Notified Body Labeling Checks

Under the IVDR (EU Regulation 2017/746), CDx labeling must meet the General Safety and Performance Requirements (GSPRs). The label must:

• Clearly specify the medicinal product it supports
• Include performance claims supported by PER (Performance Evaluation Report)
• Include language translations (based on Member State requirements)
• Display CE mark and Notified Body number

Sample labeling inclusion for IVDR:

Label Element	Example
Intended Use	Detection of EGFR exon 19 deletions in NSCLC patients for treatment with osimertinib
Device Class	Class C under Rule 3(k)
CE Mark	0123 (NB#)

PMDA Japan Labeling Considerations

In Japan, PMDA mandates bilingual labeling (Japanese and English), which must match the marketing authorization granted by MHLW. Key points include:

• Therapeutic linkage must be medically justified in Japanese patient data
• Bridging studies may be needed to support claims
• JMDN classification must be stated
• Adverse event reporting address must be present

Changes to labeling post-approval must be reported via a Partial Change Application (PCA) if they affect safety or efficacy claims.

Case Study: Global Harmonization of CDx Label

A U.S.-based diagnostic firm launched a CDx for KRAS mutation detection across the U.S., EU, and Japan. Challenges included:

• FDA required linkage to only one drug (sotorasib), while EMA permitted class-wide claims
• PMDA required additional risk disclosures for Japanese population
• IVDR demanded inclusion of CE mark and expanded stability claims

Resolution: The company developed a core IFU with region-specific annexes. This approach streamlined updates and passed inspections globally.

Discover how to build harmonized labeling SOPs at PharmaSOP.in.

Best Practices for IFU Development and Review

Developing high-quality Instructions for Use (IFU) ensures approval readiness. Recommended practices include:

• Use templates that include all global regulatory fields
• Involve cross-functional teams (RA, QA, Clinical, Medical Writing)
• Run usability studies to verify clarity and comprehension
• Perform labeling verification/validation under Design Control
• Conduct mock inspections to identify gaps

Ensure version control and audit trail documentation per ISO 13485 and FDA QSR (21 CFR 820).

Labeling Change Control: Post-Market Considerations

Labeling doesn’t end at launch. Changes must be controlled and justified. Common updates include:

• Therapeutic class expansion
• Additional mutation inclusion (e.g., EGFR exon 20)
• Software user interface changes (for digital IVDs)
• New storage conditions based on stability data

Change classification (minor vs major) impacts regulatory filing strategy. For example:

Change Type	FDA	IVDR	PMDA
Label Format Update	Annual Report	Notification	Minor Change
Therapeutic Expansion	PMA Supplement	New Consultation	PCA Filing

Language and Regional Translation Requirements

Labeling must be regionally adapted. This includes:

• EU: Translation into 24 official languages where required
• Canada: English and French dual labeling
• China: Full Simplified Chinese labeling per NMPA
• Japan: Full Japanese IFU and Summary of Safety and Effectiveness

Incorrect or incomplete translations can lead to market rejection. Always use certified translation agencies and conduct linguistic validation.

Inspection Readiness: Labeling in Regulatory Audits

Labeling is often reviewed during regulatory audits. Be prepared with:

• Labeling SOPs and training records
• Version history with change justifications
• Archived label versions and distribution records
• Risk assessments for label changes

Labeling gaps are among the top findings in FDA and Notified Body audits.

See labeling enforcement actions at FDA’s Compliance Portal.

Tips for Aligning Drug and CDx Labeling

Successful CDx labeling aligns with therapeutic labels. Recommendations include:

• Participate in joint drug-CDx labeling review committees
• Align mutation terminology (e.g., EGFR exon 19 del vs del19)
• Include consistent specimen and reporting language
• Update both labels concurrently for new indications

Joint review with Health Authority (e.g., Type C meeting with FDA) is recommended prior to PMA or NDA/BLA submission.

Conclusion

Companion diagnostic labeling is a high-stakes, high-impact component of the regulatory submission process. By aligning labeling content with regulatory requirements, therapeutic partners, and real-world data, manufacturers can enhance approval chances, minimize post-market issues, and support clinical decision-making. An effective labeling strategy must combine technical accuracy, regulatory insight, and patient safety considerations.